Distinct models to assess the cost-effectiveness of EGFR-tyrosine kinase inhibitors for the treatment of metastatic non-small cell lung cancer in the context of the Brazilian Unified Health Care System

Jr1, Pedro Aguiar; Roitberg2, Felipe; Jr3, Gilberto Lopes; Giglio4, Auro del

8009
Views

Back to summary

Open Access

Peer-Reviewed
Artigo Original

Distinct models to assess the cost-effectiveness of EGFR-tyrosine kinase inhibitors for the treatment of metastatic non-small cell lung cancer in the context of the Brazilian Unified Health Care System

Diferentes modelos para avaliar a relação custo-efetividade de inibidores de tirosina quinase do EGFR no tratamento do câncer de pulmão não pequenas células metastático no contexto do Sistema Único de Saúde

Pedro Aguiar Jr1, Felipe Roitberg2, Gilberto Lopes Jr3, Auro del Giglio4

How to cite this article

Jr1 PA, Roitberg2 F, Jr3 GL, Giglio4 Ad. Distinct models to assess the cost-effectiveness of EGFR-tyrosine kinase inhibitors for the treatment of metastatic non-small cell lung cancer in the context of the Brazilian Unified Health Care System. J Bras Pneumol. 2020;46(4):e20180255